Open AccessVancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model
Author(s) -
Lewis F. Neville,
Itamar Shalit,
Peter Warn,
Jacob T. Rendell
Publication year - 2022
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkac063
Subject(s) - urine , pharmacokinetics , urinary system , escherichia coli , medicine , carbapenem , kidney , minimum inhibitory concentration , urology , microbiology and biotechnology , pharmacology , gastroenterology , chemistry , biology , antibiotics , biochemistry , gene
STM-001, a retargeted glycopeptide, is active against MDR E. coli expressing ESBLs including carbapenemases. Herein, we assessed its capability to combat E. coli complicated urinary tract infections (cUTI) in mice driven by clinically important serine (CTX-M-15) and metallo-β-lactamases (NDM-1).